AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03867006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and Carbohydrate
Description: In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.
Study NCT00218465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW468816
Description: Pharmacotherapies for Relapse Prevention
Study NCT00218465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Study NCT02345681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study NCT04214054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moldable self-hardening biphasic calcium phosphate graft
Description: Incision was performed in the canine area then a full thickness mucoperiosteal flap was elevated and exposure of the lateral aspect of the maxillary sinus. Osteotomy of the buccal window was performed using the piezosurgery device followed by meticulous dissection of the sinus membrane. Drilling the site were implants were to be placed, guided by the preformed surgical stent. Implants of appropriate size were torqued to engage the apical aspect of the implant recipient site. The sinus was augmented with moldable self-hardening biphasic calcium phosphate. Repositioning and suturing of the flap using 3-0 black silk suture material.
Study NCT04214054 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No graft material placed - Blood Clot only
Description: A pyramidal full thickness mucoperiosteal flap was performed distal to the canine area with a crestal incision located palatally in the edentulous area and vertical extension of the incision to the buccal vestibule using Bard Parker blade number 15. The flap was reflected exposing the alveolar bone. Lateral window was performed and the sinus membrane was elevated using piezo surgery. Drilling at the sites where implants were to be placed was done using Neobiotech implant drilling Kit. Implants. Implants were placed in a self-tapping fashion using a torque wrench. Flaps were replaced back and sutured using 3-0 black silk suture material.
Study NCT01120301 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NeuroThera® Laser System
Description: Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
Study NCT01120301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroThera® Laser System
Description: Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
Study NCT03566394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Description: Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
Study NCT01104506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Study NCT01104506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Study NCT00006253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse
Description: Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
Study NCT00006253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-nurse coach
Description: Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
Study NCT02245269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02245269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02245269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT02245269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maalox
Description: Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
Study NCT03859440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSiHy Silicone hydrogel soft contact lens
Description: •Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.
Study NCT03859440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CE-marked Silicone hydrogel soft contact lens
Description: ・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay
Study NCT02642393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine
Description: capsules containing 500 mg of inosine
Study NCT02642393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
Study NCT01112774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Stimulation will be applied at 2 mA for a total of 20 minutes.
Study NCT01588340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI (Magnetic resonance imaging)
Description: Subject will complete a 15 minute scan in the MRI
Study NCT01588340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound exam
Description: The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
Study NCT04643873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity counseiling +pilates exercise group
Description: It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
Study NCT02662660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Port-sites infiltration:Bupivacaine0.25%
Description: Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
Study NCT02662660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural analgesia:Levobupivacaine0,125%
Description: Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
Study NCT01104506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mTMS
Study NCT01104506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mTMS
Study NCT04643873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity counseiling group
Description: During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
Study NCT03098550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04054479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penehyclidine
Description: Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
Study NCT04054479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
Study NCT02994082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored behavioral intervention
Description: Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
Study NCT02994082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation for elevated depressive symptoms
Description: Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
Study NCT02994082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-cessation weight gain management
Description: Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
Study NCT02994082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol use risk reduction
Description: Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
Study NCT02994082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - transdermal nicotine patch
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study NCT02994082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - nicotine lozenge
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study NCT02994082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - nicotine gum
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study NCT02994082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion sustained release
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study NCT02994082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Study NCT02994082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
Study NCT02994082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy + bupropion
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
Study NCT02994082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco quit line
Description: Referral to the Department of Veterans Affairs tobacco telephone quit line.
Study NCT02994082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
Study NCT04310436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modifying saccades by looking down to naval.
Description: Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
Study NCT04310436 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Modifying saccades by looking in air.
Description: Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
Study NCT04516070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04516070 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT04424823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LED photobiomodulation
Description: Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
Study NCT04424823 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LED photobiomodulation
Description: Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
Study NCT01935323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Study NCT01935323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Training
Study NCT01513187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib + interferon alpha 2A
Description: Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient
Study NCT00245050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine hydrochloride
Description: Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
Study NCT00245050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
Study NCT00245050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: doxorubicin HCL liposome
Description: IV, 40mg/m2
Study NCT00245050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin HCL liposome
Description: IV, 40mg/m2
Study NCT03443479 — intervention group
Intervention type: DEVICE
Intervention: Non-Invasive Ventilation
Description: Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
Study NCT03443479 — intervention group
Intervention type: DEVICE
Intervention: High-Flow Nasal Cannula
Description: Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher\&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
Study NCT02662660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole and Acetaminophen iv
Description: Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
Study NCT02662660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole and Acetaminophen iv
Description: Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
Study NCT01602718 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise training
Description: Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
Study NCT01909063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
Study NCT01909063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D, Vitamin E, and Vitamin A
Description: Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
Study NCT01909063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control, 700 mg Calcium
Description: Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
Study NCT03745716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 + azacitidine
Description: Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine
Study NCT03745716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine
Study NCT04590638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tumescent with adrenaline
Description: skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.
Study NCT04590638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tumescent without adrenaline
Description: skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
Study NCT04637932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Dilatation Tracheostomy
Description: pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure.
Study NCT00339092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Directly Observed Therapy
Description: Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
Study NCT00339092 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
Study NCT03880786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pudendal PNE test lead
Description: All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
Study NCT01152619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous repeated dose
Study NCT02526576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
Study NCT02526576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
Study NCT00683800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate (DVS) SR
Description: Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
Study NCT00683800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.